Brain Stimulation for Severe Depression
Intracalvarial Prefrontal Cortical Stimulation in Treatment-Resistant Depression
Sponsor: Inner Cosmos Inc
This observational or N/A phase trial investigates Depression Severe and is currently actively recruiting participants. Inner Cosmos Inc leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
8 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Status: Unknown → Recruiting · Phase: NA → None
-
Feb 2026 — Apr 2026 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 3 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jun 2023 — Apr 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Jun 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
Chronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull. Over time, intracalvarial cortical stimulation is intermittently activated to modulate locally and distally connected brain regions. Because of the important role played by the dorsolateral prefrontal cortex in mood regulation, the goal of this study is to apply intracalvarial prefrontal cortical stimulation (IpCS) over the dorsolateral prefrontal cortex in severely treatment-resistant depressed (TRD) patients. Per the DSM-V and Centre for Medicare and Medicaid Services (CMS) nomenclatures, TRD patients are commonly defined as those whose treatment failed to produce response or remission after 2 or more attempts of sufficient duration and treatment dose. In the investigator's study, eligible TRD subjects will have a diagnosis of major depressive disorder with a suboptimal response to an adequate dose and duration of at least two different antidepressant treatment categories. These subjects will also have had exposure and transiently (non-durably) responded to non-invasive neurostimulation. The investigator anticipates that severely Treatment Resistant Depressed (TRD) Subjects with IpCS of the dorsolateral prefrontal cortex will show a significant decrease in depression symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) at four months post-implant when compared to baseline. The investigator will enroll up to 20 subjects with severe refractory depression in an open trial, followed for up to one year. Depressive and cognitive symptoms will be rated periodically to assess the safety and efficacy of this procedure.
Contact Information
- Inner Cosmos Inc
- Massachusetts General Hospital
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .